Lexaria Bioscience Announces Positive Final Results From Human Pilot Study #5, Examining Oral Liraglutide Product

Lexaria Bioscience Corp. announces final results from Human Pilot Study #5, comparing oral DehydraTECH-liraglutide capsules to injected Saxenda branded liraglutide. The study achieved its primary safety and tolerability endpoint, demonstrating that oral DehydraTECH-liraglutide functioned comparably to injected liraglutide. The results showed a 22.7% reduction in adverse events with oral DehydraTECH-liraglutide and a 67% reduction in nausea. Weight loss was experienced by 9 out of 10 people in each study arm. The study further supports examining the pursuit of the world's first oral liraglutide product.